Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR.

Mol Cancer Res. 2008 Aug;6(8):1365-74. doi: 10.1158/1541-7786.MCR-08-0040. Epub 2008 Jul 30.

2.

DNA methylation pathway alterations in an autochthonous murine model of prostate cancer.

Morey SR, Smiraglia DJ, James SR, Yu J, Moser MT, Foster BA, Karpf AR.

Cancer Res. 2006 Dec 15;66(24):11659-67.

3.

Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.

Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR.

Mol Cell Biol. 2010 Sep;30(17):4159-74. doi: 10.1128/MCB.00235-10. Epub 2010 Jun 28.

4.
5.

Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.

McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML.

Cancer Res. 2006 Jan 1;66(1):385-92.

6.

Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.

Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA.

Cancer Biol Ther. 2007 Sep;6(9):1403-12.

PMID:
18637271
7.
8.
9.

A γ-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation.

Huang Y, Khor TO, Shu L, Saw CL, Wu TY, Suh N, Yang CS, Kong AN.

J Nutr. 2012 May;142(5):818-23. doi: 10.3945/jn.111.153114. Epub 2012 Mar 28.

10.

Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.

Mavis CK, Morey Kinney SR, Foster BA, Karpf AR.

Prostate. 2009 Sep 1;69(12):1312-24. doi: 10.1002/pros.20976.

11.

Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm.

Cho NY, Kim JH, Moon KC, Kang GH.

Virchows Arch. 2009 Jan;454(1):17-23. doi: 10.1007/s00428-008-0706-6. Epub 2008 Dec 2.

PMID:
19048291
12.

Phenotype-specific CpG island methylation events in a murine model of prostate cancer.

Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ.

Cancer Res. 2008 Jun 1;68(11):4173-82. doi: 10.1158/0008-5472.CAN-07-6715.

13.

Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate.

Morey Kinney SR, Zhang W, Pascual M, Greally JM, Gillard BM, Karasik E, Foster BA, Karpf AR.

Cancer Prev Res (Phila). 2009 Dec;2(12):1065-75. doi: 10.1158/1940-6207.CAPR-09-0010. Epub 2009 Nov 24.

14.

DNA methyltransferase and demethylase in human prostate cancer.

Patra SK, Patra A, Zhao H, Dahiya R.

Mol Carcinog. 2002 Mar;33(3):163-71.

PMID:
11870882
15.
16.

Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.

Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC, Jiang SW.

Gynecol Oncol. 2005 Mar;96(3):601-9.

PMID:
15721400
17.

Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.

Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW.

J Pathol. 2007 Aug;212(4):386-94.

PMID:
17577251
18.

Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.

Jain AK, Raina K, Agarwal R.

Cell Cycle. 2013 May 15;12(10):1598-604. doi: 10.4161/cc.24741. Epub 2013 Apr 25.

19.

Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.

Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, Campan M, Weisenberger DJ, Long T, Youn B, Fiala ES, Laird PW.

Oncogene. 2006 Apr 27;25(18):2636-45.

20.

Androgen-independent prostate cancer progression in the TRAMP model.

Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM.

Cancer Res. 1997 Nov 1;57(21):4687-91.

Supplemental Content

Support Center